Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013620)
◆英語タイトル:Sareum Holdings Plc (SAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013620
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:31
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhibitor Library). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (Checkpoint Kinase 1), Aurora+FLT3 kinase, VEGFR-3 (FLT4) kinase, Fatty Acid Synthase (FASN), Tyrosine kinase 2 (TYK2), ALK Kinase, FLT3 and Microtubule binding agents. Sareum’s Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Pampisford Cambridge, the UK.

Sareum Holdings Plc (SAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Sareum Holdings Enters Into Co-Development Agreement With The CRT Pioneer Fund And Bacit 10
Sareum And SRI International Enter Into Co-Development Agreement For Autoimmune And Inflammatory Diseases 12
Licensing Agreements 13
Sareum Holdings Enters Into Licensing Agreement With Hebei Medical University For Aurora+FLT3 Programme 13
Equity Offering 15
Sareum Holdings Raises USD1 Million in Private Placement of Shares 15
Sareum Raises USD1.6 Million in Private Placement of Shares 16
Sareum Raises USD2.2 Million in Private Placement of Shares 17
Sareum to Raise USD0.9 Million in Private Placement of Shares 18
Sareum Holdings Announces Private Placement Of Shares For US$2.7 Million 19
Sareum Decreases Size Of Private Placement Of Shares For US$0.6 Million 20
Sareum Holdings Completes Second Tranche Of Private Placement Of Shares For US$0.04 Million 21
Sareum Holdings Completes Private Placement Of US$0.8 Million 22
Sareum Holdings Plc – Key Competitors 23
Sareum Holdings Plc – Key Employees 24
Sareum Holdings Plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Oct 19, 2017: Sareum Holdings: Final Results for the year ended 30 June 2017 26
Feb 20, 2017: Sareum Holdings Announces Half-Yearly Results For The Six Months Ended 31 December 2016 27
Nov 02, 2016: Sareum Holdings: Final Results 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sareum Holdings Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sareum Holdings Plc, Deals By Therapy Area, 2011 to YTD 2017 8
Sareum Holdings Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Sareum Holdings Enters Into Co-Development Agreement With The CRT Pioneer Fund And Bacit 10
Sareum And SRI International Enter Into Co-Development Agreement For Autoimmune And Inflammatory Diseases 12
Sareum Holdings Enters Into Licensing Agreement With Hebei Medical University For Aurora+FLT3 Programme 13
Sareum Holdings Raises USD1 Million in Private Placement of Shares 15
Sareum Raises USD1.6 Million in Private Placement of Shares 16
Sareum Raises USD2.2 Million in Private Placement of Shares 17
Sareum to Raise USD0.9 Million in Private Placement of Shares 18
Sareum Holdings Announces Private Placement Of Shares For US$2.7 Million 19
Sareum Decreases Size Of Private Placement Of Shares For US$0.6 Million 20
Sareum Holdings Completes Second Tranche Of Private Placement Of Shares For US$0.04 Million 21
Sareum Holdings Completes Private Placement Of US$0.8 Million 22
Sareum Holdings Plc, Key Competitors 23
Sareum Holdings Plc, Key Employees 24
Sareum Holdings Plc, Subsidiaries 25

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析(Sareum Holdings Plc (SAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆